Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.44 |
| ▸ | CDC7 | O00311 | 1/20 | 0.44 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13048880 | 0.92 | NPC1 (0.46) | HSD17B10MAPK1HTTNPC1RAB9A | |
| SCHEMBL13048958 | 0.91 | HTT (0.56) | HSD17B10MAPK1HTTNPC1RAB9A | |
| SCHEMBL13048229 | 0.89 | NPC1 (0.44) | HSD17B10MAPK1HTTNPC1RAB9A | |
| SCHEMBL13048882 | 0.88 | NPC1 (0.43) | HSD17B10MAPK1HTTNPC1RAB9A | |
| SCHEMBL13048881 | 0.87 | NPC1 (0.42) | HSD17B10MAPK1HTTNPC1RAB9A | |
| SCHEMBL17589730 | 0.87 | ALDH1A1 (0.44) | HSD17B10MAPK1HTTNPC1RAB9A | |
| SCHEMBL13048877 | 0.87 | L3MBTL1 (0.54) | HSD17B10MAPK1HTTNPC1RAB9A | |
| SCHEMBL13048879 | 0.87 | NPC1 (0.42) | HSD17B10MAPK1HTTNPC1RAB9A | |
| SCHEMBL13048941 | 0.87 | S1PR1 (0.52) | HSD17B10MAPK1HTTNPC1RAB9A | |
| SCHEMBL16652927 | 0.86 | KDM4E (0.42) | NPC1RAB9ACYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4331364-A2 | COMPOSITIONS HAVING PESTICIDAL UTILITY AND PROCESSES RELATED THERETO | Corteva Agriscience LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-4051003-B1 | COMPOSITIONS HAVING PESTICIDAL UTILITY AND PROCESSES RELATED THERETO | CORTEVA AGRISCIENCE LLC (US) | 2023-11-29 | — | — | EP | disclosed |
| WO-2023224815-A2 | COMPOSITIONS HAVING PESTICIDAL UTILITY AND PROCESSES RELATED THERETO | CORTEVA AGRISCIENCE LLC (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230189807-A1 | COMPOSITIONS HAVING PESTICIDAL UTILITY AND PROCESSES RELATED THERETO | CORTEVA AGRISCIENCE LLC (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2021158455-A1 | COMPOSITIONS HAVING PESTICIDAL UTILITY AND PROCESSES RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230189807-A1 | COMPOSITIONS HAVING PESTICIDAL UTILITY AND PROCESSES RELATED THERETO | ACHE, DDT, PLA2G2D | HSD17B10 3587/4885MAPK1 4342/4885HTT 4058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.